Scientific Sessions 2024  /  GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics  /  Panel Discussion
Logo

American Heart Association

  109
  0

Final ID:

Panel Discussion

  • Tuttle, Katherine  ( PROVIDENCE MEDICAL RESEARCH CENTER , Spokane , Washington , United States )
    • Author Disclosures:
    Katherine Tuttle: DO have relevant financial relationships ; Consultant:Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Past (completed) ; Research Funding (PI or named investigator):Travere:Active (exists now) ; Consultant:Pfizer:Past (completed) ; Consultant:Astra Zeneca:Past (completed) ; Consultant:ProKidney:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Eli Lilly and Company:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics

Sunday, 11/17/2024 , 09:45AM - 11:00AM

Main Event

More abstracts on this topic:
The cardiovascular benefits of incretin analogues: Suggestions of indirect and direct vascular effects

Mcmurray John, Sattar Naveed

Going with the FLOW: Understanding the renal effects of GLP-1RA therapy

Tuttle Katherine, Rangaswami Janani

More abstracts from these authors:
Going with the FLOW: Understanding the renal effects of GLP-1RA therapy

Tuttle Katherine, Rangaswami Janani

Mechanisms underlying Diabetic Kidney Disease and CVD Risk

Tuttle Katherine, Pratley Richard

You have to be authorized to contact abstract author. Please, Login
Not Available